FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Shilpa Medicare Docetaxel Injection 160 mg/8mL Recall

Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only,…

Shilpa Medicare Limited · Polepally, Jadcherla, N/A

Risk level
Class II
Reported by FDA
Dec 16, 2020
Recall ID
D-0126-2021
Check your lot numberHow we source this data

Summary

Shilpa Medicare recalled Docetaxel Injection 160 mg/8mL starting Dec 8, 2020. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0126-2021 on Dec 16, 2020. Reason: CGMP Deviations. Status: Terminated.

Why it was recalled

CGMP Deviations

Product description

Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only, 8 mL Single Use Vial, Cytotoxic Agent, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, NDC 72485-216-08.

Lot numbers, UPCs & expiration codes

Lot #: 7S10185A, Exp. 10/31/2021

Where it was sold

Nationwide in the U.S.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0126-2021
Classification
Class II
Status
Terminated
Recall initiated
Dec 8, 2020
FDA report date
Dec 16, 2020
Quantity
2008 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Shilpa Medicare Limited

Original FDA data

Every field from FDA enforcement report D-0126-2021, exactly as published.

Show all FDA fields
City
Polepally, Jadcherla
Status
Terminated
Country
India
Event ID
86749
Address
S-20 To S-26, Pharm. Formulation Sez
Address (line 2)
Tsiic, Green Industrial Park
Code information
Lot #: 7S10185A, Exp. 10/31/2021
Report date
Dec 16, 2020
Product type
Drugs
Recall number
D-0126-2021
Classification
Class II
Recalling firm
Shilpa Medicare Limited
Product quantity
2008 vials
Termination date
Mar 11, 2022
Reason for recall
CGMP Deviations
Voluntary / mandated
Voluntary: Firm initiated
Product description
Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only, 8 mL Single Use Vial, Cytotoxic Agent, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, NDC 72485-216-08.
Distribution pattern
Nationwide in the U.S.
Recall initiation date
Dec 8, 2020
Initial firm notification
Letter
Center classification date
Dec 9, 2020

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0126-2021, published Dec 16, 2020. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls